Title Reinfection of cytomegalovirus in renal transplantation

Cytomegalovirus (CMV) is the most important pathogen affecting the outcome of renal transplantation. Reinfection of CMV can occur in CMV-seropositive donors and CMV seropositive recipients (D+/R+) settings because the protection against CMV conferred by preexisting immunity is limited due to its strain-dependent immune responses. To analyze the influence of CMV reinfection in renal transplantation, ELISA using fusion proteins encompassing epitope of glycoprotein H(gH) from both AD169 and Towne strains was employed before transplantation. The CMV-gH seropositive rate increased with increases in age and the rate of samples which contained antibodies against both AD169 and Towne were significantly high in the age of 50 years or over. Antibodies from HLA-DR10 and DR11 were associated with a significantly lower response rate against CMV-gH. In renal transplantation, the high degrees of antigenemia and high incidences of CMV disease are more prevalent in the CMV gH antibody-mismatched group in D+/R+ setting. The nucleotide sequence of the region of the gH epitope in the CMV-DNA extracted from the transplant recipients who showed high degree of antigenemia revealed the CMV reinfection from the donors. As a CMV indirect effect, the incidence of acute rejection in the mismatched gH antibody group was higher than that observed in the matched and D+/R− groups. The adverse events were more likely to occur in cases of D+/R+ renal transplantation with mismatched strainspecific antibodies which would indicates the risk of CMV reinfection after transplantation.

[1]  N. Inoue,et al.  Lack of antibodies against the antigen domain 2 epitope of cytomegalovirus (CMV) glycoprotein B is associated with CMV disease after renal transplantation in recipients having the same glycoprotein H serotypes as their donors , 2011, Transplant infectious disease : an official journal of the Transplantation Society.

[2]  K. Hashimoto,et al.  Association between antibody response against cytomegalovirus strain‐specific glycoprotein H epitopes and HLA‐DR , 2009, Microbiology and immunology.

[3]  K. Hashimoto,et al.  Strain-specific seroepidemiology and reinfection of cytomegalovirus. , 2008, Microbes and infection.

[4]  V. Kliem,et al.  Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  Nina Khanna,et al.  Cytomegalovirus and polyomavirus BK posttransplant. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  N. Inoue,et al.  Association of the outcome of renal transplantation with antibody response to cytomegalovirus strain-specific glycoprotein H epitopes. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  T. Reischig,et al.  The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[8]  Lanjuan Li,et al.  Association of cytomegalovirus infection with human leukocyte antigen genotypes in recipients after allogeneic liver transplantation. , 2006, Hepatobiliary & pancreatic diseases international : HBPD INT.

[9]  T. Albrecht,et al.  Human cytomegalovirus , 1990, Archives of Virology.

[10]  A. Jevnikar,et al.  Transplanting kidneys from CMV-seropositive donors to CMV-seronegative recipients is not associated with poorer renal allograft function or survival. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  D. Heisey,et al.  Association of Cytomegalovirus Disease and Acute Rejection with Graft Loss in Kidney Transplantation , 2004, Transplantation.

[12]  J. Schold,et al.  Lack of Improvement in Renal Allograft Survival Despite a Marked Decrease in Acute Rejection Rates Over the Most Recent Era , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  K. Fowler,et al.  Maternal immunity and prevention of congenital cytomegalovirus infection. , 2003, JAMA.

[14]  C. Retière,et al.  Association of glycoprotein B and immediate early-1 genotypes with human leukocyte antigen alleles in renal transplant recipients with cytomegalovirus infection , 2003, Transplantation.

[15]  A. Jevnikar,et al.  Cytomegalovirus seromismatching increases the risk of acute renal allograft rejection. , 2002, Transplantation.

[16]  P. Griffiths,et al.  Definitions of cytomegalovirus infection and disease in transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  W. Britt,et al.  Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity , 2001, The New England journal of medicine.

[18]  U. Koszinowski,et al.  Fast Screening Procedures for Random Transposon Libraries of Cloned Herpesvirus Genomes: Mutational Analysis of Human Cytomegalovirus Envelope Glycoprotein Genes , 2000, Journal of Virology.

[19]  P. Govaert,et al.  Congenital CMV-infection and hearing loss. , 2000, Acta oto-rhino-laryngologica Belgica.

[20]  D. Dunn,et al.  Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients. , 1999, Transplantation.

[21]  M. Mach,et al.  Strain-Specific Neutralization of Human Cytomegalovirus Isolates by Human Sera , 1999, Journal of Virology.

[22]  C. Söderberg-Nauclér,et al.  Productive cytomegalovirus (CMV) infection exclusively in CD13-positive peripheral blood mononuclear cells from CMV-infected individuals: implications for prevention of CMV transmission. , 1998, Transplantation.

[23]  M. Schnitzler,et al.  Impact of cytomegalovirus serology on graft survival in living related kidney transplantation: implications for donor selection. , 1997, Surgery.

[24]  M. Schnitzler,et al.  The effects of cytomegalovirus serology on graft and recipient survival in cadaveric renal transplantation: implications for organ allocation. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  W. Britt,et al.  Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response. , 1996, The Journal of general virology.

[26]  W. Britt,et al.  Antibodies specific for the antigenic domain 1 of glycoprotein B (gpUL55) of human cytomegalovirus bind to different substructures. , 1996, Virology.

[27]  W. Britt,et al.  Human cytomegalovirus glycoproteins. , 1996, Intervirology.

[28]  C. Borrebaeck,et al.  Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies , 1993, Journal of virology.

[29]  S. Chou.  Molecular epidemiology of envelope glycoprotein H of human cytomegalovirus. , 1992, The Journal of infectious diseases.

[30]  M. Mach,et al.  Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies. , 1992, The Journal of general virology.

[31]  S. Keay,et al.  Anti-idiotype antibodies that mimic gp86 of human cytomegalovirus inhibit viral fusion but not attachment , 1991, Journal of virology.